Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.70 |
| ▸ | FNTB | P49356 | 1/20 | 0.70 |
| ▸ | CNR1 | P21554 | 5/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.41 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757123 | 0.86 | FNTA (0.52) | FNTAFNTBCNR1 | |
| SCHEMBL5755955 | 0.85 | FNTA (0.51) | FNTAFNTBCNR1 | |
| SCHEMBL6303535 | 0.82 | FNTA (1.00) | FNTAFNTBCNR1CYP19A1CYP3A4 | |
| SCHEMBL4156125 | 0.81 | FNTA (0.85) | FNTAFNTBCNR1CYP19A1CYP3A4 | |
| SCHEMBL5782307 | 0.79 | CNR1 (0.76) | FNTAFNTBCNR1CYP19A1CYP3A4 | |
| SCHEMBL5754794 | 0.78 | FNTA (0.42) | FNTAFNTBCNR1 | |
| SCHEMBL6872273 | 0.77 | FNTA (0.69) | FNTAFNTBCNR1CYP19A1CYP3A4 | |
| SCHEMBL25425022 | 0.76 | IDO1 (0.50) | CYP19A1 | |
| SCHEMBL30415777 | 0.76 | IDO1 (0.50) | CYP19A1 | |
| SCHEMBL6866443 | 0.75 | FNTA (0.88) | FNTAFNTBCNR1CYP19A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135769-A1 | Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives | ANGIBAUD PATRICK R | 2006-06-22 | — | — | US | disclosed |
| EP-1351954-B1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2006-05-03 | — | — | EP | disclosed |
| US-20040067968-A1 | Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-08 | — | — | US | disclosed |
| EP-1351954-A1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002051834-A1 | FARNESYL TRANSFERASE INHIBITING 4-HETEROCYCLYL-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067968-A1 | Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline | FNTA, FNTB, ACAT2 | FNTA 1/4885FNTB 2/4885CNR1 1572/4885 |
| US-20060135769-A1 | Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives | FNTA, FNTB, RABGGTB | FNTA 1/4885FNTB 2/4885CNR1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.